Jaguar Health Reports Regaining Compliance with Nasdaq Minimum Stockholders' Equity Requirement

Jaguar Health, Inc. filed a Form 8-K to report that it believes it has regained compliance with Nasdaq Listing Rule 5550(b)(1). As of December 31, 2025, the company had reported a stockholders' deficit of approximately $18.7 million, falling below the Nasdaq Capital Market's minimum requirement of $2.5 million in stockholders' equity. The company estimates that as of April 7, 2026, its stockholders' equity now exceeds the $2.5 million threshold. This recovery is attributed to several key financial events in early 2026, including $16.0 million in non-dilutive capital from a license agreement with Woodward Specialty LLC, $3.0 million from the termination of a buy-back provision, and approximately $1.0 million from inventory sales. Additionally, the company realized a $3.4 million gain from debt extinguishment with affiliates of Chicago Venture Partners, L.P. Other contributing factors include anticipated payments from manufacturing agreements, grant revenue, and net sales of its product, Mytesi. The company maintains that these transactions have successfully addressed the previous equity deficiency.